NS 161
Alternative Names: NS-161Latest Information Update: 13 Jul 2023
At a glance
- Originator Nippon Shinyaku
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
Most Recent Events
- 12 Jul 2023 Phase-I clinical trials in Inflammation in Japan (unspecified route) (Nippon Shinyaku pipeline; July 2023)
- 29 Nov 2022 Preclinical trials in Inflammation in Japan (unspecified route) (Nippon Shinyaku pipeline; November 2022)
- 29 Nov 2022 Nippon Shinyaku plans a phase I trial for Anti-inflammatories (Nippon Shinyaku pipeline; November 2022)